Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipel...
December 16 2019 - 8:30AM
Business Wire
- Board of Directors approves first-quarter 2020 cash dividend
of $0.38 per share
- Investor Day scheduled for March 31, 2020 to showcase
mid-to-late-stage R&D pipeline progress and commercial momentum
across Biopharma businesses
Pfizer Inc. (NYSE: PFE)
announced today that its board of directors declared a
38-cent per share first-quarter 2020 dividend on the company’s
common stock, payable March 6, 2020 to holders of the Common Stock
of record at the close of business on January 31, 2020. Pfizer
increased the dividend over the fourth-quarter 2019 dividend by
approximately 6 percent to 38 cents from 36 cents per share. The
first-quarter 2020 cash dividend will be the 325th consecutive
quarterly dividend paid by Pfizer.
“The dividend increase is a testament to our commitment to
returning capital to shareholders and reflects our continued
confidence in the business and in our pipeline,” stated Dr. Albert
Bourla, Pfizer chief executive officer. “It also reinforces that
our focus on creating meaningful value for patients benefits all
our stakeholders.”
Pfizer also announced plans to host an Investor Day on Tuesday,
March 31, 2020, starting at 9:00 a.m. EDT, at its global
headquarters in New York, NY. Pfizer business executives and
scientific leadership will provide updates on the company’s
progress in advancing its R&D pipeline, specifically on product
candidates with blockbuster potential that are expected to launch
by 2025.
Dr. Bourla continued, “We look forward to highlighting the range
of therapeutic areas and modalities in our R&D pipeline,
demonstrating the growth momentum in our Biopharma businesses and
providing an opportunity to meet scientific and commercial
leadership in each of our core therapeutic areas. We are excited to
share key aspects of our strategy to deliver sustainable, long-term
growth by developing transformational medicines and vaccines that
address some of the world’s greatest unmet needs in
healthcare.”
Invitations for in-person attendance will be distributed in
coming weeks. A live webcast, including audio, video and
presentation slides, will be accessible on the Pfizer’s Investor
Relations website (www.pfizer.com/investors) at the time of the
meeting. Interested parties unable to attend in-person or watch the
live webcast will be able to view and listen to an archived copy of
the webcast, which will be available on Pfizer's Investor Relations
website following the conclusion of the event.
Pfizer Inc.: Breakthroughs that change patients’
lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.pfizer.com. In addition, to
learn more, please visit us on www.pfizer.com and follow us on
Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us
on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is
as of December 16, 2019. The forward-looking statements in the
Investor Day webcast on March 31, 2020 speak only as of the
original date of the webcast. The Company assumes no obligation to
update forward-looking statements contained in this release or the
webcast as a result of new information or future events or
developments.
This release contains forward-looking information about the
Company’s pipeline, growth opportunities or prospects and
shareholder returns that involves substantial risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. The Investor
Day webcast may include forward-looking statements about, among
other things, our anticipated future operating and financial
performance, business plans and prospects, expectations for our
product pipeline, in-line products and product candidates,
strategic reviews, capital allocation objectives,
business-development plans, benefits anticipated from the
reorganization of our commercial operations in 2019, plans for and
prospects of our acquisitions and other business development
activities, including our proposed transaction with Mylan N.V.
(Mylan) to combine Upjohn and Mylan to create a new global
pharmaceutical company, our acquisition of Array BioPharma Inc. and
our transaction with GSK that combined our respective consumer
healthcare businesses into a new consumer healthcare joint venture,
our ability to successfully capitalize on growth opportunities or
prospects, manufacturing and product supply and plans relating to
share repurchases and dividends, among other things, that are
subject to substantial risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
by such statements. Risks and uncertainties include, among other
things, the uncertainties inherent in research and development,
including the ability to meet anticipated clinical endpoints,
commencement and/or completion dates for our clinical trials,
regulatory submission dates, regulatory approval dates and/or
launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities; whether
regulatory authorities will be satisfied with the design of and
results from our clinical studies; whether and when any drug
applications may be filed for any of our product candidates in any
jurisdiction; whether and when regulatory authorities in any
jurisdictions where any applications are pending or may be
submitted for our product candidates may approve any such
applications, which will depend on myriad factors, including making
a determination as to whether the product’s benefits outweigh its
known risks and determination of the product’s efficacy, and, if
approved, whether they will be commercially successful; decisions
by regulatory authorities impacting labeling, manufacturing
processes, safety and/or other matters that could affect the
availability or commercial potential of our product candidates; the
uncertainties inherent in business and financial planning,
including, without limitation, risks related to Pfizer’s – or any
of our joint venture or acquisition counterparties’ – business and
prospects, adverse developments in Pfizer’s markets, or adverse
developments in the U.S. or global capital markets, credit markets,
regulatory environment or economies generally; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results,” as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191216005193/en/
Investors: Ryan Crowe (212) 733-8160
Media: Patricia Kelly (212) 733-3810
Pfizer (NYSE:PFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Sep 2023 to Sep 2024